Lotte Biologics to spotlight dual-site ADC CDMO strategy at World ADC Asia, BIO USA 2025

Lotte Biologics said it will participate in two major global biotech events this June -- the World ADC Asia Summit in Korea and the BIO International Convention in the U.S. -- to showcase its differentiated contract development and manufacturing organization (CDMO) capabilities, particularly in the field of antibody-drug conjugates (ADCs).

The company will first attend the World ADC Asia Summit, taking place from June 10 to 12 in Incheon. Now in its fourth year, the event has grown into a leading regional platform for ADC-focused collaboration. Lotte Biologics aims to expand its network of potential clients in Asia and strengthen its presence in the global ADC CDMO landscape.

Afterward, the company will make its fourth consecutive appearance at the BIO International Convention (BIO USA), the world’s largest biotech gathering, held this year from June 16 to 19 in Boston.

Lotte Biologics said its exhibition booth in Boston will feature a private meeting space designed to host confidential partnering discussions with global pharmaceutical companies and biotech innovators.

The company also plans to present a roadmap for its dual-site manufacturing strategy, which includes both the Syracuse Bio Campus in the U.S. and the Incheon-based Songdo Bio Campus in Korea.

Notably, the company’s ADC capabilities have garnered growing attention following the unveiling of its proprietary SoluFlex Link platform at the J.P. Morgan Healthcare Conference in January. In April, Lotte Biologics signed a manufacturing agreement with an Asia-based biotech firm to produce clinical trial material for an ADC candidate, accelerating its expansion in the high-growth ADC market.

Lotte Biologics also plans to highlight its one-stop ADC service offering -- ranging from development to commercial production -- and the competitive quality infrastructure of its upcoming Songdo site, which is scheduled to begin commercial operations in 2027.

The dual-site strategy allows the company to provide geographically flexible manufacturing solutions tailored to the needs of multinational clients.

“Our participation in these international conferences will allow us to present the concrete business strategy built on the synergy between the Syracuse and Songdo campuses,” a Lotte Biologics official said. “We will continue to expand our global competitiveness through active partnering with potential clients worldwide.”